Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2009 - 2026)

Regeneron Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $8.8 billion for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 4.84% year-over-year to $8.8 billion in Q1 2026; TTM through Mar 2026 was $8.8 billion, a 4.84% increase from a year earlier, with the FY2025 full-year figure at $8.6 billion, down 4.52% from the prior year.
• Cash & Current Investments rose to $8.8 billion in Q1 2026 per REGN's latest filing, from $8.6 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $10.8 billion in Q4 2023 and bottomed at $7.0 billion in Q3 2022.
• The 5-year median for Cash & Current Investments is $8.8 billion (2026), against an average of $8.8 billion.
• Across the five-year window, Cash & Current Investments soared 101.23% in 2022 and retreated 23.85% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $7.7 billion in 2022, then jumped by 40.07% to $10.8 billion in 2023, then dropped by 16.9% to $9.0 billion in 2024, then slipped by 4.52% to $8.6 billion in 2025, then increased by 1.73% to $8.8 billion in 2026.
• Per Business Quant, the three latest REGN Cash & Current Investments figures stand at $8.8 billion (Q1 2026), $8.6 billion (Q4 2025), and $8.4 billion (Q3 2025).